These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10768634)

  • 21. Progressive hemifacial atrophy with localized scleroderma.
    Tan E; Kürkçüoğlu N; Atalağ M; Gököz A; Zileli T
    Eur Neurol; 1989; 29(1):15-7. PubMed ID: 2707287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of two different units of botulinum toxin type a evaluated by computed tomography and electromyographic measurements of human masseter muscle.
    Kim JH; Shin JH; Kim ST; Kim CY
    Plast Reconstr Surg; 2007 Feb; 119(2):711-7. PubMed ID: 17230111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mild Cognitive Impairment as a single sign of brain hemiatrophy in patient with Localized Scleroderma and Parry-Romberg Syndrome.
    Klimiec E; Klimkowicz-Mrowiec A
    Neurol Neurochir Pol; 2016; 50(3):215-8. PubMed ID: 27154452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parry-Romberg syndrome combined with hemifacial spasm: association or chance event?
    Wei-Feng Z; Yi-Bo Z; Jun Z; Wei-Guo Z
    J Craniofac Surg; 2011 Nov; 22(6):2397-9. PubMed ID: 22134291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Commentary: The effect of botulinum toxin type A injection on lower facial contouring evaluated using a three-dimensional laser scan.
    Ahn KY
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2167. PubMed ID: 21244566
    [No Abstract]   [Full Text] [Related]  

  • 26. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment.
    von Lindern JJ; Niederhagen B; Appel T; Bergé S; Reich RH
    Plast Reconstr Surg; 2001 Feb; 107(2):327-32. PubMed ID: 11214045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Parry-Romberg progressive facial hemiatrophy and localized scleroderma. Nosologic and pathogenic problems].
    Auvinet C; Glacet-Bernard A; Coscas G; Cornelis P; Cadot M; Meyringnac C
    J Fr Ophtalmol; 1989; 12(3):169-73. PubMed ID: 2695557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of botulinum toxin type A injection on lower facial contouring evaluated using a three-dimensional laser scan.
    Shim WH; Yoon SH; Park JH; Choi YC; Kim ST
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2161-6. PubMed ID: 21134047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progressive hemifacial atrophy with linear scleroderma.
    Dervis E; Dervis E
    Pediatr Dermatol; 2005; 22(5):436-9. PubMed ID: 16190996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Masseter inhibitory reflex in movement disorders. Huntington's chorea, Parkinson's disease, dystonia, and unilateral masticatory spasm.
    Cruccu G; Pauletti G; Agostino R; Berardelli A; Manfredi M
    Electroencephalogr Clin Neurophysiol; 1991 Feb; 81(1):24-30. PubMed ID: 1705216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Masseter Muscle and Its Role in Facial Contouring, Aging, and Quality of Life: A Literature Review.
    Almukhtar RM; Fabi SG
    Plast Reconstr Surg; 2019 Jan; 143(1):39e-48e. PubMed ID: 30303926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Botulinum toxin for masseter hypertrophy.
    Al-Muharraqi MA; Fedorowicz Z; Al Bareeq J; Al Bareeq R; Nasser M
    Cochrane Database Syst Rev; 2009 Jan; (1):CD007510. PubMed ID: 19160335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Facial hemiatrophy, homolateral cervical linear scleroderma and thyroid disease].
    Claudy AL; Segault D; Rousset H; Moulin G
    Ann Dermatol Venereol; 1992; 119(8):543-5. PubMed ID: 1485755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemimasticatory and hemifacial spasm: a common pathophysiology?
    Thompson PD; Carroll WM
    Clin Exp Neurol; 1983; 19():110-9. PubMed ID: 6568919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement.
    To EW; Ahuja AT; Ho WS; King WW; Wong WK; Pang PC; Hui AC
    Br J Plast Surg; 2001 Apr; 54(3):197-200. PubMed ID: 11254408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Idiopathic and sclerodermic facial hemiatrophy with generalized myopathy. Clinical, electromyographic and histologic examinations of six patients].
    Runne U; Fasshauer K
    Hautarzt; 1977 Jan; 28(1):10-7. PubMed ID: 838576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemimasticatory spasm: a series of 17 cases and a comprehensive review of the literature.
    Yoshida K
    Front Neurol; 2024; 15():1377289. PubMed ID: 38566853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Total hemiatrophy. Association with localized scleroderma, Schönlein-Henoch nephritis, and paroxysmal nocturnal hemoglobinuria.
    Kuto F; Sakaguchi T; Horasawa Y; Hayashi M; Hirasawa Y; Tokuhiro H
    Arch Intern Med; 1985 Apr; 145(4):731-3. PubMed ID: 3985735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between Conventional Blind Injections and Ultrasound-Guided Injections of Botulinum Toxin Type A into the Masseter: A Clinical Trial.
    Bae H; Kim J; Seo KK; Hu KS; Kim ST; Kim HJ
    Toxins (Basel); 2020 Sep; 12(9):. PubMed ID: 32932891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lower facial contouring with botulinum toxin type A.
    Tartaro G; Rauso R; Santagata M; Santillo V; Itro A
    J Craniofac Surg; 2008 Nov; 19(6):1613-7. PubMed ID: 19098563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.